Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;27(10):2725-2728.
doi: 10.3201/eid2710.211509. Epub 2021 Aug 5.

SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy

Aurélie Truffot, Julien Andréani, Marion Le Maréchal, Alban Caporossi, Olivier Epaulard, Raphaele Germi, Pascal Poignard, Sylvie Larrat

SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy

Aurélie Truffot et al. Emerg Infect Dis. 2021 Oct.

Abstract

A 72-year-old immunocompromised man infected with severe acute respiratory syndrome coronavirus 2 received bamlanivimab monotherapy. Viral evolution was monitored in nasopharyngeal and blood samples by melting curve analysis of single-nucleotide polymorphisms and whole-genome sequencing. Rapid emergence of spike receptor binding domain mutations was found, associated with a compartmentalization of viral populations.

Keywords: COVID-19; SARS-CoV-2; bamlanivimab; compartmentalization; coronavirus disease; coronaviruses; immunotherapy; monoclonal antibody; monotherapy; respiratory infections; selection; severe acute respiratory syndrome coronavirus 2; variants; viruses; whole-genome sequencing; zoonoses.

PubMed Disclaimer

Figures

Figure
Figure
Severe acute respiratory syndrome coronavirus 2 variants in immunocompromised patient in France given antibody monotherapy showing compartmentalization and variation of mutation frequency for the spike protein. Mutations of interest are indicated by days after bamlanivimab infusion. A) NP samples; B) blood samples. The upper dashed horizontal line indicates 95% and the lower dashed horizontal line indicates 5%. B, blood; NP, nasopharyngeal.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sjaarda CP, Rustom N, Evans GA, Huang D, Perez-Patrigeon S, Hudson ML, et al. Phylogenomics reveals viral sources, transmission, and potential superinfection in early-stage COVID-19 patients in Ontario, Canada. Sci Rep. 2021;11:3697. 10.1038/s41598-021-83355-1 - DOI - PMC - PubMed
    1. Li H. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics. 2018;34:3094–100. 10.1093/bioinformatics/bty191 - DOI - PMC - PubMed
    1. Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325:632–44. 10.1001/jama.2021.0202 - DOI - PMC - PubMed
    1. Lohr B, Niemann D, Verheyen J. Bamlanivimab treatment leads to rapid selection of immune escape variant carrying E484K mutation in a B.1.1.7 infected and immunosuppressed patient. Clin Infect Dis. 2021;•••:ciab392; Epub ahead of print. 10.1093/cid/ciab392 - DOI - PubMed
    1. Baum A, Fulton BO, Wloga E, Copin R, Pascal KE, Russo V, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369:1014–8. 10.1126/science.abd0831 - DOI - PMC - PubMed

Substances

-